U.S. markets open in 3 hours 23 minutes
  • S&P Futures

    4,234.50
    +24.75 (+0.59%)
     
  • Dow Futures

    33,476.00
    +172.00 (+0.52%)
     
  • Nasdaq Futures

    13,401.50
    +90.25 (+0.68%)
     
  • Russell 2000 Futures

    1,990.60
    +14.30 (+0.72%)
     
  • Crude Oil

    94.57
    +0.23 (+0.24%)
     
  • Gold

    1,802.60
    -4.60 (-0.25%)
     
  • Silver

    20.26
    -0.09 (-0.44%)
     
  • EUR/USD

    1.0298
    -0.0028 (-0.27%)
     
  • 10-Yr Bond

    2.8880
    0.0000 (0.00%)
     
  • Vix

    20.04
    +0.30 (+1.52%)
     
  • GBP/USD

    1.2141
    -0.0061 (-0.50%)
     
  • USD/JPY

    133.3750
    +0.3760 (+0.28%)
     
  • BTC-USD

    23,995.19
    -466.22 (-1.91%)
     
  • CMC Crypto 200

    570.10
    -4.64 (-0.81%)
     
  • FTSE 100

    7,516.18
    +50.27 (+0.67%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc.

SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a panel discussion at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 3:15 pm ET.

A live webcast of the panel discussion will be available under the ‘Investors & News’ section of the Finch website and will be archived for approximately 30 days.

About Finch Therapeutics

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease.

Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com